← All stocks

Neumora Therapeutics, Inc.

NMRA No buying or selling
CIK 0001885522 #3643 in the set updated 21 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
$0.00
$0.00 against sales at will

By person

9 insiders · 0 transactions
16.8×

Paul L. Berns holds 16.8 times base salary in stock. $11.80M of shares against $700.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Paul L. Berns last reported holding, valued at $1.60, the price Common Stock was last bought or sold at on the open market here, on 21 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
BERNS PAUL L
See Remarks
7,395,185
$11.80M
−5.4%
Burow Kristina
Director
6,046,907
$9.65M
+46.4%
ARCH Venture Partners XII, LLC entity
10% owner
6,046,907
$9.65M
+46.4%
ARCH Venture Partners X, LLC entity
10% owner
6,046,907
$9.65M
+46.4%
Lenz Robert A.
Head of R&D
309,092
$493.25K
−5.9%
Pinto Joshua
President & CEO
209,950
$335.04K
−6.3%
Aurora Daljit Singh
See Remarks
48,750
$77.80K
−77.0%
Milligan Michael Lee
See Remarks
21,034
$33.57K
−14.0%
Fust Matthew K
Director
20,100
$32.08K
0.0%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 0
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 0
History held since 18 Sep 2023